Disclosure: The authors declared no conflict of interest.
The expression of FTO in human adipose tissue is influenced by fat depot, adiposity, and insulin sensitivity
Article first published online: 26 JUL 2013
Copyright © 2012 The Obesity Society
Volume 21, Issue 6, pages 1165–1173, June 2013
How to Cite
Bravard, A., Veilleux, A., Disse, E., Laville, M., Vidal, H., Tchernof, A. and Rieusset, J. (2013), The expression of FTO in human adipose tissue is influenced by fat depot, adiposity, and insulin sensitivity. Obesity, 21: 1165–1173. doi: 10.1002/oby.20110
Funding agencies: This work was supported by INSERM and the Agence Nationale pour la Recherche (ANR-09-JCJC-0116 from JR). Work on the Canadian samples was supported by the Canadian Institutes of Health Research (Grant MOP-64182). A.B. is a recipient of a grant from Servier Laboratories and ANRT. A.T. is the recipient of a senior investigator scholarship from Fonds de la recherche en santé du Québec. GlaxoSmithKline sponsored the rosiglitazone treatment study
- Issue published online: 26 JUL 2013
- Article first published online: 26 JUL 2013
- Accepted manuscript online: 5 NOV 2012 05:51PM EST
- Manuscript Accepted: SEP 2012
- Manuscript Received: JUN 2011
- INSERM and the Agence Nationale pour la Recherche. Grant Number: ANR-09-JCJC-0116
- Work on the Canadian samples was supported by the Canadian Institutes of Health Research. Grant Number: MOP-64182
- senior investigator scholarship from Fonds de la recherche en santé du Québec
- GlaxoSmithKline sponsored the rosiglitazone treatment study
Objective: The fat mass and obesity associated (FTO) gene is related to obesity, but the regulation of FTO expression in adipose tissue is not fully understood. We investigated FTO expression in paired subcutaneous and omental adipose tissues (SAT and OAT) from healthy women undergoing gynecological surgeries, and its relation with adiposity and insulin sensitivity.
Design and Methods: FTO expression in SAT of type 2 diabetic patients treated or not with Rosiglitazone was also compared.
Results: Both the mRNA and protein levels of FTO were higher in OAT from women than in SAT. Only OAT FTO protein levels negatively correlated with BMI and body fat mass, whereas SAT FTO mRNA levels were negatively correlated with subcutaneous fat deposition. In addition, SAT FTO mRNA and protein levels were increased in insulin resistant women (high HOMA) compared to insulin sensitive women (low HOMA), whereas OAT FTO expression was not different between these two subgroups. Interestingly, FTO mRNA levels were increased in SAT of type 2 diabetic patients, and treatment of diabetics with Rosiglitazone improved insulin sensitivity and reduced SAT FTO mRNA levels. Lastly, FTO expression was transiently increased in the early phase of 3T3-L1 cell differentiation, which coincides with the induction of PPARγ2 expression. However, partial reduction of FTO did not impact PPARγ2 expression and adipocyte differentiation.
Conclusion: Therefore, FTO gene expression is higher in OAT than in SAT in lean to moderately obese women. OAT FTO expression is associated with adiposity, whereas SAT FTO expression is associated with insulin sensitivity. These associations are independent of an effect of FTO on adipocyte differentiation.